The presence of binding sites for both the ER axis and E2F1 in many promoters of amplicon genes confirms the potential for regulation that could switch from ER dominant in luminal A cancers to E2F1 programs in luminal B cancers, or upon progression, when hormonal resistance develops. Here, E2F1 is linked to cancer.